# A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

> **NCT07636772** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Akeso** · enrollment: 132 (estimated)

## Conditions studied

- Urothelial Carcinoma (UC)

## Interventions

- **DRUG:** AK146D1 for injection
- **DRUG:** AK112 Injection

## Key facts

- **NCT ID:** NCT07636772
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2028-08-24
- **Final completion:** 2028-08-24
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636772, "A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07636772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*